Minimal residual disease (MRD) assessment before and after autologous hematopoietic cell transplantation (AutoHCT) and maintenance for multiple myeloma (MM) …

TE Hahn, PK Wallace, R Fraser, M Fei… - Biology of Blood and …, 2019 - astctjournal.org
PRIMeR is the first US-based ancillary study of MRD assessment by multiparameter flow
cytometry (MFC). Patients were enrolled on a national 3-arm RCT (BMT CTN 0702,
STAMiNA trial, ClinicalTrials. gov Identifier: NCT01109004) comparing 1) tandem auto-HCT,
2) single auto-HCT and 3) single auto-HCT, 4 cycles of lenalidomide, bortezomib,
dexamethasone consolidation (auto+ RVD); all 3 treatment arms included continuous
lenalidomide maintenance until MM progression. STAMiNA opened to accrual before …